TY - JOUR
T1 - Imbricaric acid and perlatolic acid
T2 - multi-targeting anti-inflammatory depsides from Cetrelia monachorum
AU - Oettl, Sarah K
AU - Gerstmeier, Jana
AU - Khan, Shafaat Y
AU - Wiechmann, Katja
AU - Bauer, Julia
AU - Atanasov, Atanas G
AU - Malainer, Clemens
AU - Awad, Ezzat M
AU - Uhrin, Pavel
AU - Heiss, Elke H
AU - Waltenberger, Birgit
AU - Remias, Daniel
AU - Breuss, Johannes M
AU - Boustie, Joel
AU - Dirsch, Verena M
AU - Stuppner, Hermann
AU - Werz, Oliver
AU - Rollinger, Judith M
PY - 2013/10/9
Y1 - 2013/10/9
N2 - In vitro screening of 17 Alpine lichen species for their inhibitory activity against 5-lipoxygenase, microsomal prostaglandin E2 synthase-1 and nuclear factor kappa B revealed Cetrelia monachorum (Zahlbr.) W.L. Culb. & C.F. Culb. As conceivable source for novel anti-inflammatory compounds. Phytochemical investigation of the ethanolic crude extract resulted in the isolation and identification of 11 constituents, belonging to depsides and derivatives of orsellinic acid, olivetolic acid and olivetol. The two depsides imbricaric acid (4) and perlatolic acid (5) approved dual inhibitory activities on microsomal prostaglandin E2 synthase-1 (IC50 = 1.9 and 0.4 µM, resp.) and on 5-lipoxygenase tested in a cell-based assay (IC50 = 5.3 and 1.8 µM, resp.) and on purified enzyme (IC50 = 3.5 and 0.4 µM, resp.). Additionally, these two main constituents quantified in the extract with 15.22% (4) and 9.10% (5) showed significant inhibition of tumor necrosis factor alpha-induced nuclear factor kappa B activation in luciferase reporter cells with IC50 values of 2.0 and 7.0 µM, respectively. In a murine in vivo model of inflammation, 5 impaired the inflammatory, thioglycollate-induced recruitment of leukocytes to the peritoneum. The potent inhibitory effects on the three identified targets attest 4 and 5 a pronounced multi-target anti-inflammatory profile which warrants further investigation on their pharmacokinetics and in vivo efficacy.
AB - In vitro screening of 17 Alpine lichen species for their inhibitory activity against 5-lipoxygenase, microsomal prostaglandin E2 synthase-1 and nuclear factor kappa B revealed Cetrelia monachorum (Zahlbr.) W.L. Culb. & C.F. Culb. As conceivable source for novel anti-inflammatory compounds. Phytochemical investigation of the ethanolic crude extract resulted in the isolation and identification of 11 constituents, belonging to depsides and derivatives of orsellinic acid, olivetolic acid and olivetol. The two depsides imbricaric acid (4) and perlatolic acid (5) approved dual inhibitory activities on microsomal prostaglandin E2 synthase-1 (IC50 = 1.9 and 0.4 µM, resp.) and on 5-lipoxygenase tested in a cell-based assay (IC50 = 5.3 and 1.8 µM, resp.) and on purified enzyme (IC50 = 3.5 and 0.4 µM, resp.). Additionally, these two main constituents quantified in the extract with 15.22% (4) and 9.10% (5) showed significant inhibition of tumor necrosis factor alpha-induced nuclear factor kappa B activation in luciferase reporter cells with IC50 values of 2.0 and 7.0 µM, respectively. In a murine in vivo model of inflammation, 5 impaired the inflammatory, thioglycollate-induced recruitment of leukocytes to the peritoneum. The potent inhibitory effects on the three identified targets attest 4 and 5 a pronounced multi-target anti-inflammatory profile which warrants further investigation on their pharmacokinetics and in vivo efficacy.
KW - Animals
KW - Anti-Inflammatory Agents/isolation & purification
KW - Ascomycota/chemistry
KW - Benzoates/isolation & purification
KW - Depsides/isolation & purification
KW - Drug Evaluation, Preclinical
KW - HEK293 Cells
KW - Humans
KW - Inhibitory Concentration 50
KW - Leukocytes/drug effects
KW - Male
KW - Mice
KW - Mice, Inbred C57BL
KW - Peritoneum/drug effects
UR - http://www.scopus.com/inward/record.url?scp=84885113540&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0076929
DO - 10.1371/journal.pone.0076929
M3 - Article
C2 - 24130812
SN - 1932-6203
VL - 8
SP - e76929
JO - PLoS ONE
JF - PLoS ONE
IS - 10
M1 - e76929
ER -